Lead sponsor
Texas Diabetes & Endocrinology, P.A.
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
0
Active
31
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
Terminated
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection PortHbA1c 6.5-9%not applicableTerminated31